Bone metastases from differentiated thyroid cancer: characteristics and prognostic factors in a multicenter series
Authors' conclusion
Our study reflects the management of patients with bone metastases from differentiated thyroid carcinoma in real clinical practice in several centers in southern Spain. Overall survival at 5 and 10 years was lower in patients who were not treated with I131, had nodal involvement and/or had other metastases.
Study context
- Population
- Patients diagnosed with bone metastases (BMs) from differentiated thyroid carcinoma (DTC), 1980–2021, several centers in southern Spain
- Participants
- 63 patients
- Outcome
- Characteristics, survival and prognostic factors
- Follow-up
- 5- and 10-year survival
Methodological detailsmulticenter
- Multicenter
Main finding
As reported in the abstract
5 and 10 years
- 5-year overall survival
- 42.4%
- 10-year overall survival
- 20.4%
- Lymph node involvement, 5 years: HR
- 2.916 (95% CI 1.013-8.391; P = 0.047)
- Treatment with I131, 5 years: HR
- 0.214 (95% CI 0.069-0.665; P = 0.008)
- Other metastases, 10 years: HR
- 6.844 (95% CI 1.017-46.05; P = 0.048)
- Treatment with I131, 10 years: HR (95% CI 0.058-0.913); P = 0.037)
- 0.23
- Died
- 34 (54%)
Observational data: associations, not effects.
Further findings
Patient and treatment characteristics
- Median follow-up from BM diagnosis (months)
- 35 (15-68)
- Synchronous BMs
- 30 (48.4%)
- Papillary variant
- 38 (60.3%)
- Multiple BMs
- 32 (50.8%)
- Spine location
- 60.3%
- Other metastases
- 77.8%
- Pulmonary metastases
- 69.8%
- Received I131
- 54 (85.9%)
- BM uptake
- 31 (49.2%)
- Multikinase inhibitors
- 25 (39.7%)
Safety
- Skeletal-related events
- 34 (54%)
Original publication
Bone metastases from differentiated thyroid cancer: characteristics and prognostic factors in a multicenter series. Eur Thyroid J. Published 23 August 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →